Orion-yhtyma Oy

Other

University of California

Orion Corporation

Hormos Medical Corporation

Michael W DeGregorio

Lauri V Kangas

Pirkko Harkonen

Kaija Halonen

Kalervo Vaananen

Aire Maria Laine

Valerie Wiebe

Kauko O Kurkela

Adrian Llewllyn Harris

Tatu Miettinen

Eero Mantyla

The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (TRIP) compound with an effective amount of the therapeutic agent. In particular embodiments, the TRIP compound enhances the immune response of the subject to the therapeutic agent. In some embodiments, the TRIP compound is administered in different dosing schedules to provide a biphasic immunomodulation effect.

Methods for immunomodulation of cancer and infectious disease therapy

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

Method for the alleviation of dyspareunia in women

This invention concerns a method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering to the woman an effective amount of the compound (deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof, or a metabolite thereof.

Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

Serum cholesterol lowering agent

A pharmaceutical composition is provided for use in the prevention or treatment of osteoporosis comprising a therapeutically effective amount of a compound of formula (I) ##STR1## wherein R.sub.1 and R.sub.2 are independently H or OH, for the treatment or prevention of osteoporosis and a pharmaceutically acceptable carrier.

Triphenylethylenes compositions

Triphenylethylenes for the prevention and treatment of osteoporosis

Topical administration of toremifene and its metabolites

This invention relates to the use of a compound comprising toremifene or its metabolites N-demethyltoremifene or 4-hydroxytoremifene or its non-toxic pharmaceutically acceptable salts for the reversal of multidrug resistance of cancer cells to cytotoxic drugs in the treatment of cancer with such cytotoxic drugs.

Use of toremifene and its metabolites for the reversal of multidrug

Growing community of inventors

Granite Bay, CA, United States of America

Michael W DeGregorio